Central Nervous System
This session will focus on recent and emerging research in radiation oncology for patients with brain and spine tumors. Special emphasis will be placed on radiosurgery dose/fractionation selection, IDH inhibition in glioma and glioma contouring/targeting. Future directions for brain tumor research will also be discussed, including several ongoing clinical trials.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Identify reasonable approaches to selecting dose and fractionation in stereotactic radiosurgery for brain tumors.
- Appropriately critique the recent evidence in support of IDH inhibitors in patients with glioma.
- Appropriately select eligible patients with brain metastases for stereotactic radiosurgery.
Faculty:
A list of all meeting faculty and Individual presenter disclosures can be found on the Schedule of Events page.
Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee webpage.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.